Radio Frequency Identification (RFID) in Pharmaceuticals Market Report 2025

The radio frequency identification (RFID) in pharmaceuticals market size has grown rapidly in recent years. It will grow from $5.48 billion in 2024 to $6.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth during the historic period can be attributed to the increase in pharmaceutical exports, the rise of e-commerce, the growth in clinical trials, the demand for tamper-evident RFID solutions, and the expansion of patient-centric healthcare delivery models.

The radio frequency identification (RFID) in pharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $9.12 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the increasing incidences of counterfeit drugs, rising healthcare awareness, expanding hospital automation, growing demand for real-time tracking, and increased investment in digital supply chain solutions. Key trends during the forecast period include technological advancements, improvements in radio frequency identification tag design, integration with cloud-based platforms, developments in pharmaceutical-specific inlays, and progress in supply chain digitization.

The rising incidents of counterfeit drugs are expected to drive the growth of the radio frequency identification (RFID) in pharmaceuticals market moving forward. Counterfeit drugs, also known as counterfeit medicines, are pharmaceutical products that are intentionally and fraudulently mislabeled regarding their identity or source. The surge in counterfeit drug cases is largely attributed to the rapid expansion of online pharmacies, which has made it easier for counterfeiters to distribute fake medicines directly to consumers, bypassing traditional regulatory controls and complicating detection efforts. RFID in pharmaceuticals helps combat counterfeit drugs by providing secure, traceable data that verifies product authenticity at every stage of the supply chain. For example, in December 2024, the American Chemical Society, a US-based nonprofit scientific organization, reported 6,987 counterfeit drug incidents across 142 countries in 2023, marking a 4% increase from 2022. Therefore, the rising cases of counterfeit drugs are fueling the growth of the RFID in pharmaceuticals market.

Leading companies in the RFID in pharmaceuticals market are concentrating on developing advanced RFID-enabled labels to improve product traceability, optimize inventory management, and counter the increasing threat of counterfeit drugs. RFID-enabled labels are smart tags that use radio frequency technology to wirelessly identify, track, and authenticate pharmaceutical products throughout the supply chain. For instance, in May 2023, Fresenius Kabi AG, a Germany-based pharmaceutical company, introduced Rocuronium Bromide Injection with advanced RFID-enabled labeling to enhance medication tracking, inventory control, and patient safety within healthcare settings. This product is supplied as a 50 mg per 5 mL multiple-dose vial for intravenous use by trained medical personnel. The injection incorporates advanced RFID smart labeling that enables real-time tracking, streamlines inventory processes, and helps reduce medication errors.

In April 2023, Impinj Inc., a US-based technology firm, acquired Voyantic Ltd for an undisclosed sum. With this acquisition, Impinj aims to bolster its position in the RFID industry and expand its portfolio with advanced RFID testing and measurement solutions to enhance performance and innovation. Voyantic Ltd. is a Finland-based company that specializes in RFID testing, measurement, and quality assurance solutions for RFID tags and systems used in pharmaceuticals.

Major players in the radio frequency identification (rfid) in pharmaceuticals market are Fujitsu Limited, NXP Semiconductors NV, Avery Dennison Corporation, Zebra Technologies Corporation, CCL Industries Inc., HID Global Corporation, Checkpoint Systems Inc, Datalogic SpA, Impinj Inc, Schreiner Group GmbH & Co KG, Invengo Information Technology Co Ltd, GAO RFID Inc., Lowry Solutions Inc., Terso Solutions Inc., Xerafy Singapore Pte Ltd., Tageos SAS, SML Group Limited, Syrma SGS Technology Limited, Omnia Technologies Private Limited, and identytag GmbH & Co KG.

North America was the largest region in the radio frequency identification (RFID) in pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in radio frequency identification (RFID) in pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the radio frequency identification (RFID) in pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radio frequency identification (RFID) in pharmaceuticals market consists of revenues earned by entities providing services such as drug authentication, real-time tracking and tracing of medications, inventory management, anti-counterfeiting solutions, and regulatory compliance. The market value includes the value of related goods sold by the service provider or included within the service offering. The radio frequency identification (RFID) in pharmaceuticals market also includes sales of fixed readers, tracing systems, and verification systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The radio frequency identification (RFID) in the pharmaceuticals market research report is one of a series of new reports that provides radio frequency identification (RFID) in the pharmaceuticals market statistics, including radio frequency identification (RFID) in the pharmaceuticals industry global market size, regional shares, competitors with a radio frequency identification (RFID) in the pharmaceuticals market share, detailed radio frequency identification (RFID) in the pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radio frequency identification (RFID) in the pharmaceuticals industry. This radio frequency identification (RFID) in the pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radio frequency identification (RFID) in pharmaceuticals is a wireless technology that employs electronic tags equipped with chips and antennas to automatically identify, track, and manage medicines throughout the entire supply chain, from manufacturing to final use. This technology improves patient safety, ensures regulatory compliance, and optimizes operations by enabling fast, contactless, and precise verification of drug authenticity and movement at every stage.

The primary types of radio frequency identification (RFID) in pharmaceuticals include chipped radio frequency identification and chipless radio frequency identification. Chipped radio frequency identification involves RFID technology that utilizes tags embedded with microchips and antennas, permitting the storage and wireless transmission of unique identification data, tracking details, and product history. These can be read by compatible RFID readers for real-time authentication, monitoring, and management of pharmaceutical products across the supply chain. These systems are supported by various components such as RFID tags, RFID readers, middleware software, integration services, and data management software, and are implemented in accordance with regulatory compliance standards including Food and Drug Administration compliance, European Union Falsified Medicines Directive, Good Distribution Practices, serialization requirements, and tracking and tracing regulations. Radio frequency identification technologies are applied in multiple areas, including drug track and trace systems, asset tracking, patient safety, and other relevant applications, serving a diverse range of end users such as pharmaceutical manufacturers, hospitals and healthcare providers, pharmacies and drug wholesalers, research and development laboratories, and logistics and supply chain companies.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.